DAWN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DAWN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-28), the Trailing Annual Dividend Yield of Day One Biopharmaceuticals is 0.00%.
The historical rank and industry rank for Day One Biopharmaceuticals's Dividend Yield % or its related term are showing as below:
Day One Biopharmaceuticals's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.
As of today (2024-05-28), the Forward Dividend Yield % of Day One Biopharmaceuticals is 0.00%.
Day One Biopharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Day One Biopharmaceuticals's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Dividend Yield % | - | - | - | - | - |
Day One Biopharmaceuticals Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Day One Biopharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Day One Biopharmaceuticals (NAS:DAWN) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
York Charles N Ii | officer: COO, CFO and Secretary | 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746 |
Samuel C. Blackman | officer: Chief Medical Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Jeremy Bender | director, officer: Chief Executive Officer | 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Ai Day 1 Llc | 10 percent owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Julie Papanek Grant | director | 2765 SAND HILL ROAD, MENLO PARK CA 94025 |
Canaan Xi L.p. | 10 percent owner | 2765 SAND HILL RD, MENLO PARK CA 94025 |
Garry A Nicholson | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Atlas Venture Opportunity Fund Ii, L.p. | 10 percent owner | 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
Michael Gladstone | director | 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Takeda Ventures, Inc. | 10 percent owner | 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
John A. Josey | director | C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235 |
From GuruFocus
By Value_Insider Value_Insider • 10-17-2022
By sperokesalga sperokesalga • 05-26-2023
By Marketwired • 08-07-2023
By GlobeNewswire • 09-12-2023
By sperokesalga sperokesalga • 06-06-2023
By GlobeNewswire GlobeNewswire • 06-07-2023
By GlobeNewswire GlobeNewswire • 06-04-2023
By GuruFocus Research GuruFocus Editor • 01-25-2023
By sperokesalga sperokesalga • 06-12-2023
By sperokesalga sperokesalga • 06-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.